The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

Pfizer builds on early Ibrance lead as Novartis, Lilly rivals inch closer

Pfizer's Ibrance has already been prescribed to more than 20,000 patients, and the company says it has a "very heavy" clinical trial program testing it in multiple types of breast cancer and beyond.

Top exec exits as Pfizer redraws org chart for post-megamerger future

Pfizer is shaking up its corporate structure again as it prepares to merge with Allergan and further lays the groundwork for a potential split in a few years. The structural rejig pushes out Geno Germano, who has been leading Pfizer's global innovative pharma business, and elevates one top Allergan manager, Bill Meury, to the combined company's commercial leadership team.

Pfizer keeps pushing on early hit Ibrance as Novartis, Lilly rivals near market

Pfizer's Ibrance has been steamrolling since it nabbed an early FDA go-ahead last February. And even with competition coming up the pipeline from the company's Big Pharma rivals, Pfizer intends to keep it that way.

Celltrion's take on J&J's Remicade is 'highly similar' to the original, FDA says

FDA staff signaled support for Celltrion's biosimilar of Johnson & Johnson's Remicade in documents released ahead of a key panel vote, a positive development for the South Korean company as it works with Pfizer to tap the U.S. market.

Affinivax nets another $2.5M from Gates Foundation to advance Prevnar competitor

Cambridge, MA-based Affinivax launched in November 2014 with a $4 million Gates Foundation investment and plans to develop a pneumococcal vaccine that it believes could go beyond Prevnar, the best-selling vaccine in the world. Now, the biotech is announcing $2.5 million in follow-on funding from the Gates Foundation, which it will use to advance its lead candidate, CEO Steve Brugger told FierceVaccines.

Merck, J&J, Pfizer consider joining Zika vaccine race

While the early entrants to the race for a Zika vaccine have been on the smaller side--think Hawaii Biotech, NewLink Genetics and Inovio Pharmaceuticals--the big guns are now joining in. Just one day after Sanofi announced a firm plan to develop a vaccine for the mosquito-borne disease, a parade of Big Pharmas has joined GlaxoSmithKline in "evaluating their technologies" for the potential of developing a Zika vaccine.

Prevnar's 2015 sales surged to $6B-plus on new CDC nod in adults

After a monster year, the "low-hanging fruit" is gone for Pfizer's Prevnar 13 as the company looks to penetrate the adult market in the U.S. But fear not, investors, execs said Tuesday--there's plenty left in Europe.

Pfizer's busy Q4 in emerging markets a prelude for the big show

Pfizer came through a hectic fourth quarter with a major deal pending and at work on integrating an earlier one while at the same time trying to identify niches for both in emerging markets and particularly China.

Samsung's Benepali biosimilar wins first EU sales in Norway

Norway became the first overseas country to approve the Enbrel biosimilar made by Samsung Bioepis for sale, coming two weeks after the drug, Benepali, was approved by the European Commission.

Pfizer's vaccine sales leap in 2015 thanks to Prevnar 13

Riding Prevnar 13 uptake, Pfizer's vaccines unit capped off a big growth year on Tuesday, reporting Q4 sales increases of 45% and full-year 2015 growth of 44%.